OHDSI MEETINGS THIS WEEK
Vocabulary / Population Visualization Working Group - Kick off meeting Tuesday at 11am EThttps://meetings.webex.com/collabs/#/meetings/detail?uuid=M0TCF7ADLE0712J9UOYPULZAJA-D1JL&rnd=695083.27830
Patient-Level Prediction Workgroup (Eastern Hemisphere) - Wednesday at 3pm Hong Kong Timehttps://global.gotomeeting.com/join/972917661
Population-Level Estimation Workgroup (Western Hemisphere) - Thursday at 12pm EThttps://meetings.webex.com/collabs/#/meetings/detail?uuid=M3T9BZV9RSB6YNDM8WDDZMI19D-D1JL
Hadoop - Friday at 3pm EThttp://cloudera.webex.com/meet/sdolley
ANNOUNCEMENTS
OHDSI F2F - Registration is now open for the OHDSI F2F to take place on March 17-18th at GeorgiaTech in Atlanta. Register here:http://www.ohdsi.org/events/2017-ohdsi-collaborator-face-to-face/
Diversity is our strength
COMMUNITY PUBLICATIONS
How did the Introduction of Biosimilar Filgrastim Influence the Prescribing Pattern of Granulocyte Colony-Stimulating Factors? Results from a Multicentre, Population-Based Study, from Five Italian Centres in the Years 2009-2014.
I Marcianò, Y Ingrasciotta, F Giorgianni, J Bolcato, A Chinellato, R Pirolo, A Di Giorgio, S Manna, V Ientile, R Gini, M Santarpia, AA Genazzani, I Uomo, M Pastorello, SW Pollina Addario, S Scondotto, P Cananzi, R Da Cas, G Traversa, M Rossi, L Sottosanti, AP Caputi and G Trifirò,
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy , Aug 2016
Granulocyte colony-stimulating factors (G-CSFs) are biological products for which the main indication of use is chemotherapy-induced neutropenia. Biosimilars of G-CSFs have been available in Europe since 2007.The objective of this study was to investigate the prescribing pattern of G-CSFs in five Italian centres using different healthcare policy interventions to promote the use of biosimilars in routine care.This retrospective, population-based drug utilization study was conducted during the years 2009-2014 using the administrative databases of the Caserta, Treviso and Palermo Local Health Units (LHUs) and the Tuscany and Umbria regions. G-CSF users were characterized and the prevalence of use, proportion of biosimilar users and switching pattern of different G-CSFs were evaluated over time and across centres.Overall, 30,247 patients were treated with G-CSFs in the years 2009-2014, of which 29,083 (96.2 %) were naïve users. The overall prevalence of G-CSF use increased from 0.8 per 1000 inhabitants in 2009 to 1.1 per 1000 in 2014. An increase in the proportion of the use of the biosimilar filgrastim by the total G-CSF users was observed in all centres: from 0.2 % (2009) to 66.2 % (2014). However, heterogeneity across different centres was reported, with the largest increase in Treviso LHU (from 0 to 89.1 % from 2009 to 2014). During the first year of treatment, switching between different G-CSFs was frequent (20.3 %).Heterogeneity in the use of G-CSF and, in particular, biosimilar filgrastim across different Italian centres was observed, probably due to different regional healthcare policy interventions. During the first year of treatment, switching between different G-CSFs was frequent. Considering the impact of biological drugs on pharmaceutical expenses, it is necessary to harmonize healthcare policies promoting the use of biological drugs with the lowest cost.
Work environment and quality improvement in healthcare.
U Iqbal, S Syed-Abdul and YC Li,
International journal for quality in health care : journal of the International Society for Quality in Health Care , Apr 2016
The relationship between the failure to eradicate Helicobacter pylori and previous antibiotics use.
SG Lim, RW Park, SJ Shin, D Yoon, JK Kang, JC Hwang, SS Kim, JH Kim and KM Lee,
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver , Apr 2016
The previous use of antibiotics is known to correlate positively with antibiotic resistance; whether this is also the case in the eradication of Helicobacter pylori infection is unclear.To investigate the relationship between the previous use of antibiotics and the failure of eradication therapy in H. pylori infection.The relationship between the clinical parameters and the failure of H. pylori eradication was analyzed in patients administered standard triple therapy and then assessed for the eradication of H. pylori based on a C13-urea breath test.In a multivariate analysis, failure rates increased significantly in patients with a history of clarithromycin (odds ratio [OR], 4.445) or other macrolides (OR, 2.407) use, who were female (OR, 1.339), or who were older than 60 years of age (OR, 1.326). The eradication failure rate in patients with a history of macrolides use for >2 weeks was significantly higher than if the duration of use was <2 weeks (44.8% vs. 29.3%, p=0.047).A patient's history of macrolides is a useful predictor of the likelihood of standard triple therapy failure in H. pylori eradication. The alternatives such as a bismuth-based quadruple or a levofloxacin-containing therapy should be considered in patients treated with macrolides for >2 weeks.
Risk of cardiac valvulopathy with use of bisphosphonates: a population-based, multi-country case-control study.
PM Coloma, M de Ridder, I Bezemer, RM Herings, R Gini, S Pecchioli, L Scotti, P Rijnbeek, M Mosseveld, J van der Lei, G Trifirò and M Sturkenboom,
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA , May 2016
Analyses of healthcare data from 30 million individuals in three countries showed that current use of bisphosphonates may be associated with a small increased risk of cardiac valvulopathy (vs. those not exposed within the previous year), although confounding cannot be entirely ruled out. The observed tendency for decreased valvulopathy risk with cumulative duration of bisphosphonate use >6 months may even indicate a protective effect with prolonged use. Further studies are still needed to evaluate whether bisphosphonates increase or decrease the risk of valvulopathy.A signal of cardiac valve disorders with use of bisphosphonates was identified in the literature and EudraVigilance database, which contains reports of suspected adverse drug reactions from worldwide sources. The aim of this study was to evaluate the association using population-based healthcare data.This was a case-control study among users of bisphosphonates and other drugs for osteoporosis in six healthcare databases covering over 30 million individuals in Italy, Netherlands and the UK from 1996 to 2012. Prescriptions/dispensations were used to assess drug exposure. Newly diagnosed cases of cardiac valvulopathy were identified via disease codes/free-text search. Controls were matched to each case by age, sex, database and index date. Adjusted odds ratios (ORs) were estimated using conditional logistic regression for the pooled data and meta-analysis of individual database risk estimates.A small but statistically significant association was found between exposure to bisphosphonates as a class and risk of valvulopathy. Overall risk was 18 % higher (95 % CI 12-23 %) in those currently exposed to any bisphosphonate (mainly alendronate and risedronate) vs. those not exposed within the previous year. Risk of valve regurgitation was 14 % higher (95 % CI 7-22 %). Decreased valvulopathy risk was observed with longer cumulative duration of bisphosphonate use, compared to use of less than 6 months. Meta-analyses of database-specific estimates confirmed results from pooled analyses.The observed increased risks of cardiac valvulopathy with bisphosphonate use, although statistically significant, were quite small and unlikely to be clinically significant. Further studies are still needed to evaluate whether bisphosphonates increase or decrease the risk of valvulopathy and to investigate possible mechanisms for the association.
Atypical Antipsychotics and the Risk of Falls and Fractures Among Older Adults: An Emulation Analysis and an Evaluation of Additional Confounding Control Strategies.
Ten Simple Rules to Enable Multi-site Collaborations through Data Sharinghttp://journals.plos.org/ploscompbiol/article?id=10.1371/journal.pcbi.1005278
